Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating atherosclerosis or restenosis using microtubule stabilizing agent

a technology of atherosclerosis and stabilizing agent, applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of affecting the elderly, the cost of this disease in human suffering and material resources is almost incalculable, and the vascular disese is the leading cause of death and disability in the developed world, so as to prevent or reduce the development of atherosclerosis or restenosis, prevent or redu

Inactive Publication Date: 2007-05-31
UNITED STATES OF AMERICA
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020] In accordance with these and other objects of the present invention, a method of preventing or reducing atherosclerosis or restenosis is provided, which comprises treatment with a therapeutically effective amount of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. A therapeutically effective amount of agent is an amount sufficient to prevent or reduce the development of atherosclerosis or restenosis.
[0021] This method provides an effective way of preventing or reducing the development of atherosclerosis or restenosis in those patients susceptible to such disease. Additionally, because of the low dose of chemotherapeutic agent used, the chance of a patient developing adverse reactions is potentially reduced.

Problems solved by technology

Vascular diseese is the leading cause of death and disability in the developed world, particularly afflicting the elderly.
The cost of this disease in terms of human suffering and of material resources is almost incalculable.
Atherosclerosis is the most common form of vascular disease and leads to insufficient blood supply to critical body organs, resulting in heart attack, stroke, and kidney failure.
Additionally, atherosclerosis causes major complications in those suffering from hypertension and diabetes, as well as tobacco smokers.
These VSMC become abnormally proliferative, secreting substances (growth factors, tissue-degradation enzymes and other proteins) which enable them to invade and spread into the inner vessel lining, blocking blood flow and making that vessel abnormally susceptible to being completely blocked by local blood clotting, resulting in the death of the tissue served by that artery.
The most effective way to prevent this disease is at the cellular level, as opposed to repeated revascularization surgery which can carry a significant risk of complications or death, consumes time and money, and is inconvenient to the patient.
However, it is has been demonstrated that the incidence and severity of allergic reactions is affected by the dosage and rate of taxol infusion (Weiss, R. B., et al.
Additionally, it has been observed that the incidence of severe cardiac events is low in patients receiving taxol alone.
During angioplasty, intraarterial balloon catheter inflation results in deendothelialization, disruption of the internal elastic lamina, and injury to medial smooth muscle cells.
The art fails to suggest the use of a microtubule stabilizing agent such as taxol in preventing or reducing this disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
  • Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
  • Method for treating atherosclerosis or restenosis using microtubule stabilizing agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0035] The in vitro ability of cultured VSMCs, pretreated with different taxol concentrations, to invade filters coated with reconstituted basement membrane proteins was tested to evaluate how taxol-induced microtubule bundling would impair cell processes necessary for in vivo neointimal formation.

[0036] Vascular Smooth Muscle Cells (VSMCs) were isolated by collagenase / elasase enzymatic digestion of the medial layers of the rat aorta obtained from 6 month old Wistar rats. The cells were maintained in culture with 10% fetal calf serum, high glucose DMEM, and amino acid supplement. Cell cultures were maintabed at 37° C. in 5% CO2.

[0037] After 18 -hour taxol pre-treatment in culture, cells were fixed in 3.7% formalin, permeabilized with 1% Triton X-100, and polymerized tubulin was labelled with mouse anti-β-tubulin antibody (SMI 62 monoclonal antibody to polymerized β-tubulin, Paragon Biotec, Inc., Baltimore, Md.). Secondary labelling was achieved with silver-enhanced, 1 nm gold-conj...

example 2

[0042] To confirm the fact that microtubule stabilization and hyperpolymerization is the critical and sufficient factor involved in taxol-inhibition of VSMC invasiveness, the chemoinvasion (Boyden chamber) assay was run with deuterium oxide (2H2O, heavy water). Deuterium oxide enhances microtubulel / tubulin polymerization via a mechanism distinct from that of taxol. A combination of the isotope and solvent effects of deuterium oxide reversibly increases microtubule polymerization both by reducing the critical concentration for polymerization for αβ-tubulin heterodimers via enhanced tubulin hydrophobic interactions (Itoh, T. J., et al. (1984) Biochim. Biophys. Acta., 800:21-27), and by converting a population of unpolymerizable tubulin to the polymerizable form (Takahashi, T. C., et al. (1984) Cell Struct. Funct., 9:45-52).

[0043] VSMC's were isolated by collagense / elastase enzymatic digestion of the medial layers of the rat aorta obtained from 6 month old Wistar rats. The cells were ...

example 3

[0047] In addition to cell recruitment and migration, the various growth regulatory molecules elaborated after arterial injury, such as PDGF and bFGF, are also implicated in mitogenesis and cellular proliferation. To measure the effect of taxol on VSMC DNA synthesis, [3H]thymidine incorporation was measured. VSMCs were plated at 4.5×104 on 24-well plates. Following 5 hr. incubation in 10% FCS+DMEM, 0.5 mCi [3H]thymidine was added and the incubation continued for an additional 16 hrs. Cells were washed twice with phosphate-buffered saline, extracted with 10% TCA for 2 hrs. on ice, then centrifuged at 2,000 g for 10 mins. Supernatants were decanted and pellets were solubilized in 0.5 ml of 1 N NaOH. After neutralizing with 0.5 ml of 1 N HCl, [3H]thymidine uptake was determined by a Beckman liquid scintillation counter. VSMCs were treated with the various concentrations of taxol for both the 18 hr. prior to the addition of the thymidine and during thymidine incorporation. Each conditio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefor. In particular, it is a method of preventing or reducing atherosclerosis or resenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or a water soluble taxol derivative. The low dose used in the present invention prevents artery blockage while minimizing any negative side effects associated with the drug.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a method of treating patients at risk of developing atherosclerosis or restenosis. [0002] More particularly, the invention relates to treatment of these patients with a low dose taxol solution to prevent or reduce the development of atherosclerosis or restenosis. BACKGROUND OF THE INVENTION [0003] Vascular diseese is the leading cause of death and disability in the developed world, particularly afflicting the elderly. In the United States alone, despite recent encouraging declines, cardiovascular disease is still responsible for almost one million fatalities each year and more than one half of all deaths; almost 5 million persons afflicted with cardiovascular disease are hospitalized each year. The cost of this disease in terms of human suffering and of material resources is almost incalculable. [0004] Atherosclerosis is the most common form of vascular disease and leads to insufficient blood supply to critical body orga...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/337A61K9/00C07D305/14A61K31/335A61L31/16A61P9/00A61P9/10
CPCA61K9/0024A61K31/335A61K31/337A61L31/16A61L2300/416A61L2300/602Y10S514/824A61P9/00A61P9/10A61P9/12A61P3/10
Inventor KINSELLA, JAMES L.SOLLOTT, STEVEN J.
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com